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Abstract
The limited sensitivity of serological tests for mycobacterial antigens has encouraged the development of a nanoparticle probe speciﬁc
for the extrapulmonary form of Mycobacterium tuberculosis (Mtb). We developed an innovative probe comprised of super-paramagnetic
iron oxide (SPIO) nanoparticles conjugated with Mtb surface antibody (MtbsAb-nanoparticles) to provide ultrasensitive imaging of bio-
markers involved in extrapulmonary Mtb infection. MtbsAb-nanoparticles were signiﬁcantly conjugated with Mtb bacilli. The extent of
contrast enhancement reduction on magnetic resonance imaging (MRI) for Mtb and human monocytic THP1 cells was proportional to
the concentration of MtbsAb-nanoparticles. When MtbsAb-nanoparticles were intravenously injected into mice bearing Mtb granulomas,
the granulomatous site showed a 14-fold greater reduction in signal intensity enhancement on T2-weighted MR images compared with
an opposing site that received PBS injection. Mtb sAb-nanoparticles represent a new non-invasive technology for the diagnosis of extra-
pulmonary Mtb.
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Introduction
Tuberculosis (TB) is a major public health problem that
affects nearly one-third of the world’s population [1]. For
example, in 2005, 8.8 million new TB cases and 1.6 million
deaths attributed to TB were reported, making TB the sec-
ond leading cause of infectious disease deaths [2]. Extrapul-
monary TB (ETB) is an even greater diagnostic challenge
than primary TB (PTB), as it occurs less frequently and with
little liberation of bacilli. In addition, it is usually localized at
sites that are difﬁcult to access, such as lymph nodes, the
pleura and osteoarticular areas [3] Further, invasive proce-
dures required to obtain adequate clinical specimens are
complex and sometimes risky, which makes bacteriological
conﬁrmation difﬁcult, thus requiring more invasive proce-
dures to obtain adequate samples [4–6]. Also in ETB, fewer
bacilli cause much greater damage secondary to bacterial
invasion of solid organs, which induces severe immunological
reactions. Thus, the combination of small numbers of bacilli
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and inaccessible sites makes bacteriological conﬁrmation of
extrapulmonary TB more difﬁcult [7].
The diagnosis of extrapulmonary mycobacterial infection is
also difﬁcult to establish due to its non-speciﬁc clinical pre-
sentation. Negative sputum smears for acid-fast bacilli, lack
of granulomatous tissue on histopathology or failure to cul-
ture Mycobacterium tuberculosis do not exclude a diagnosis.
Currently, commercial antibody detection tests for ETB
serve no role in clinical care or case detection due to their
highly variable sensitivities (range, 0.00–1.00) and speciﬁcities
(range, 0.59–1.00) for all extrapulmonary sites combined [8].
Enzyme-linked immunospot (ELISPOT) assay for interferon-c,
a cytokine produced by activated T cells after exposure to
Mycobacterium tuberculosis (Mtb) antigens, early secretory
antigenic target 6 (ESAT-6) and culture ﬁltrate protein 10
(CFP-10) have been used for the diagnoses of latent and
active TB; however, results vary between different disease
sites and few studies have investigated the speciﬁcities and
sensitivities of these assays for diagnosing extrapulmonary
TB [9–11]. Thus, novel diagnostic modalities are needed.
Additional tests for ETB are frequently negative, including
negative skin PPD tests and pseudo-negative QuantiFERON-
TB tests [12]. Although QuantiFERON TB-2G and immune-
based blood assays, which do not require a specimen from
the affected organ for microbiological or histological exami-
nation, may serve as alternative diagnostic tools [9,13,14].
Other TB diagnostic methods include serological tests by
enzyme-linked immunosorbent assays (ELISA), which do not
have sufﬁcient sensitivity and speciﬁcity to be useful [15,16].
The development of DNA ampliﬁcation techniques, such
as the polymerase chain reaction (PCR), shows promise.
However, their use in TB diagnosis is limited as most studies
to date only used small sample sizes with poorly explained
reference standards and clinical criteria, making comparisons
among these studies difﬁcult [17,18]. Other disadvantages of
using PCR are the need for an adequate infrastructure and
personnel qualiﬁed to perform this technique [7]. Therefore,
an ideal test for latent ETB is still urgently needed.
Advances in molecular imaging are aimed at developing
and testing novel methods that can image speciﬁc molecular
pathways in vivo, particularly those directly involved in dis-
ease processes [19,20]. The detection of biological materials
using organic ﬂuorescent labelling has become widespread in
the life sciences, including biological imaging and diagnostics
[21]. Functional limitations of organic ﬂuorescent dyes used
in biotechnology applications have resulted in the develop-
ment of new labelling systems [22]. Highly sensitive and
highly speciﬁc probes that lack the intrinsic limitations of
organic dyes and ﬂuorescent proteins are of considerable
interest in many research areas [22,23].
Luminescent colloidal nanometer-sized semiconductor par-
ticles have the potential to overcome the intrinsic limitations
of organic ﬂuorescent dyes [24–26]. These nanocrystals have
been covalently linked to biorecognition molecules, such as
peptides, antibodies, nucleic acids and small-molecule ligands,
for use as ﬂuorescent probes [27–29]. Compared with organic
ﬂuorophores, these quantum dots (QDs) have unique optical
and electronic properties, including size- and composition-tun-
able ﬂuorescence emissions ranging from visible to infrared
wavelengths, large absorption coefﬁcients across a wide spec-
tral range and high brightness levels and photostability. So long
as the semiconductor core is well encapsulated, the speciﬁc
photochemical reactions that cause organic dyes to photo-
bleach are not a problem with inorganic nanoparticles. Due to
their broad excitation proﬁles and narrow, symmetric emis-
sion spectra, they are also well suited for optical multiplexing
to encode genes, proteins and small-molecule libraries.
Recently, super-paramagnetic iron oxide (SPIO) nanoparti-
cles have been used to increase the sensitivity and speciﬁcity
of MRI systems [30,31]. These clearly delineate precise struc-
tures at the molecular level and provide a valuable tool to
thoroughly study antibody–antigen and parasite–host interac-
tions.
We have designed a new molecular imaging probe com-
prised of SPIO nanoparticles conjugated with Mtb surface
antibody (MtbsAb-nanoparticles). SPIO nanoparticle probes
have the advantage of being non-toxic, or minimally toxic to
cells and tissues under normal physiological conditions
[32,33]. In addition, due to their paramagnetic properties,
they can be detected at low concentrations and provide pre-
cise magnetic resonance images at the molecular level. More-
over, iron oxide paramagnetic nanoparticles incur no risk of
allergic immune reactions, as iron ions participate in normal
physiological metabolism.
In this exploratory study, we evaluated the sensitivity and
speciﬁcity of these probes using both in vitro cell cultures and
in vivo animal assays with the goal of developing an ultrasensi-
tive imaging agent for detecting extrapulmonary mycobacte-
rial infection.
Methods
All reagents used for synthesis were purchased from com-
mercial sources. These included: ferric chloride hexahydrate
(FeCl3Æ6H2O), ferrous chloride tetrahydrate (FeCl2Æ4H2O)
and NH4OH from Fluka, Seelze, Germany; epichlorohydrin,
2,2¢-(ethylenedioxy)bis(ethylamine) (EDBE), 1-hydroxybenzo-
triazole (HOBt) and (benzotriazol-1-yloxy) tripyrrolidinophos-
phonium hexaﬂuorophosphate (PyBop) from Sigma-Aldrich,
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Seelze, Germany; dextran (T-40), Sephacryl S-300 and Sepha-
dex G-25 from GE Healthcare Bio-sciences AB, Uppsala,
Sweden; and SPECTRUM molecular porous membrane tub-
ing from Spectrum Laboratories Inc, Rancho Dominguez,
CA, USA. TB surface antibodies (TB surface antibody- Poly-
clonal Antibody to Mtb (Rabbit anti-M tuberculosis) BP2027)
were purchased from Acris Antibodies GmbH, Im Himmelr-
eich, Hiddenhausen.
Synthesis of SPIO
Magnetic iron oxide coated dextran nanoparticles were pre-
pared by mixing dextran T-40 (5 mL; 50% w/w) with an aque-
ous solution containing FeCl3Æ6H2O (0.45 g; 2.77 mmol) and
FeCl2Æ4H2O (0.32 g; 2.52 mmol). The mixture was stirred vig-
orously at room temperature followed by the rapid addition of
NH4OH (10 mL; 7.5% v/v). The resulting black suspension was
stirred continuously for 1 h and subsequently centrifuged at
17 300 g for 10 min in order to remove aggregated material.
The super-paramagnetic iron oxide nanoparticles (SPIO) were
separated from unbound dextran T-40 by gel ﬁltration chroma-
tography with Sephacryl S-300. The reaction mixture (5 mL)
was applied to a 2.5 · 33 cm column and eluted with buffer
solution containing 0.1 M Na acetate and 0.15 M NaCl at pH
7.0. The puriﬁed magnetic iron oxide coated dextran nanopar-
ticles were collected in the void volume, and column eluates
were assayed for iron at 330 nm by hydrochloric acid and for
dextran at 490 nm by the phenol/sulphuric acid method [34].
The iron oxide coated dextran nanoparticles were proven
by FT-IR. FT-IR (KBr)(cm)1): m~ = 3300 (O–H), 2800 (–
CH2– stretch).
Synthesis of SPIO-EDBE-SA
We synthesized SPIO conjugated with EDBE using previously
reported methods [35,36]. SPIO-EDBE and succinic anhy-
dride (1 g, 10 lmol; SA) in NaOH (5 M; 10 mL) was stirred
for 24 h at room temperature; the solution was dialyzed
using SPECTRUM molecular porous membrane tubing
(12 000–14 000 MW cut-off) against 20 changes of distilled
water (2 L each).
Synthesis of SPIO-MtbsAb
SPIO-EDBE-SA (100 lL) at a concentration of 4 mg/mL of Fe
was added to 400 lL (4.5 mg/mL) M. tuberculosis (BP2027;
Acris, Himmelreich, Germany) Ab using 1-hydroxybenzo-
triazole (HOBt) and (benzotriazol-1-yloxy) tripyrrolidino-
phosphonium hexaﬂuorophosphate (PyBop) as catalysts, then
stirred for 24 h at room temperature. The solution was sep-
arated from unbound antibody by gel ﬁltration chromatogra-
phy on Sephadex G-25. The reaction mixture (5 mL) was
applied to a 2.5 · 33 cm column and eluted with PBS buffer.
The formation of Ab–nanoparticles was conﬁrmed with a
bicinchoninic acid protein assay kit [37].
Transmission electron microscope (TEM) measurements
Particle average core size, size distribution and morphology
were evaluated using a transmission electron microscope
(JEOL JEM-2000 EX II; Tokyo, Japan) at a voltage of 100 kV.
The composite dispersion was drop-cast onto a 200-mesh
copper grid (Agar Scientiﬁc, Emitek, Ashford, UK), which
was then air-dried at room temperature before loading onto
the microscope.
Relaxation time measurements
Relaxation time values (T1 and T2) of the aqueous solution of
MtbsAb-nanoparticles were measured to determine relaxivi-
ties: r1 and r2. All measurements were made using a NMR
relaxometer (NMS-120 Minispec, Bruker, Bremen, Germany)
operating at 20 MHz and 37.0 ± 0.1C. Before each mea-
surement, the relaxometer was tuned and calibrated. Both r1
and r2 values were determined from eight data points gener-
ated by inversion-recovery and a Carr-Purcell-Meiboom-Gill
pulse sequence.
Mycobacteria
The vaccination strain used was M. bovis BCG Pasteur Me´r-
ieux, which was grown to mid-log phase in Middlebrook 7H9
broth (Difco, Sparks, MD, USA) supplemented with 10% (v/
v) ADC, 0.05% (v/v) Tween 80 and 0.2% (v/v) glycerol at
37C. Cultures were aliquoted into 1 mL tubes and stored
at )80C until use. Thawed aliquots were diluted with dou-
ble-distilled sterile water to the desired inoculum concentra-
tions. The use of M. bovis BCG in this study was limited by
biosafety and grading of the author’s laboratory. The lyophi-
lized vaccine/bacteria stock was reconstituted with Sauton’s
medium and then diluted with ddH2O for further use.
Acid-fast bacteria Ziehl–Neelsen stain and Berlin blue stain
Tuberculosis smears to examine for positive acid-fast bacilli
used Ziehl–Neelsen staining, as previously described [38].
SPIO MtbsAb probes were incubated with Mtb broth for
30 min and then stained with Berlin blue to determine if the
probe conjugated to the bacteria [39].
In vitro cell culture and imaging
Human monocytic THP-1 cells were cultured in RPMI 1640
(Gibco/Invitrogen, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (FBS) (Gibco/Invitrogen), 50 mg/L gen-
tamycin sulfate (Gibco), 100 units/mL penicillin G sodium
(Gibco), 100 lg streptomycin sulphate (Gibco) and 0.25 mg/L
fungizone (Gibco). We used THP-1 cells because monocytes
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represent the ﬁrst site of bacterial contact in extrapulmonary
infection. Cells were cultured in a 5% CO2 incubator at 37C.
Super-paramagnetic iron oxide TBsAb probes (2 mM)
were incubated with 106 CFU M. bovis BCG only or with
106 CFU M. bovis BCG pre-incubated with 1 · 107 activated
THP-1 cells in 1 mL Eppendorf tubes in a 5% CO2 incubator
at 37C for 1 h. The tubes were then centrifuged and the
supernatant was removed. The pellets were redissolved in
200 lL of medium. MRI scans (3.0-T, Sigma; GE Medical Sys-
tems, Milwaukee, WI, USA) were performed to evaluate the
sensitivity and speciﬁcity of the probes using the in vitro cell
culture system. All samples were scanned with a fast gradient
echo pulse sequence (TR/TE/ﬂip angel 500/20/10).
Mice
Five C57BL/6 mice were obtained from the animal facilities
at Taipei Medical University. The mice were housed individu-
ally in polycarbonate cages in a temperature- and humidity-
controlled environment. Ambient lighting was automatically
controlled to provide 12-h light and 12-h dark cycles. The
mice were kept under speciﬁc pathogen-free conditions and
fed autoclaved food and water ad libitum. All procedures
were reviewed and approved by the Taipei Medical Univer-
sity Laboratory Animal Care Committee. At 8 weeks of age,
the mice were housed in appropriate biological containment
facilities at Wang-Fan Hospital under barrier conditions in a
biosafety level III animal laboratory. Following local ethical
review, all animal work was carried out in accordance with
the Animal (Scientiﬁc Procedures) Act of 1986.
BCG vaccination
Mice were inoculated with a live attenuated strain of M. bovis
BCG (Connaught strain; ImmuCyst Aventis) that was pro-
vided by Pasteur Me´rieux. On the day of inoculation, the
lyophilized vaccine/ bacteria stock was ﬁrst reconstituted in
Sauton’s medium and then diluted with saline to the desired
concentration. A volume of 0.1 mL per mouse was then
injected intradermally into the left or right dorsal scapular
skin. A dose of 107 CFU per mouse was selected based on
methods described in the literature [40]. Negative control
mice were given saline. After 1 month, infection was veriﬁed
by histology of bacteria-inoculated tissue samples.
Histology and immunohistochemistry
Bacteria inoculated-tissue samples were removed en bloc and
ﬁxed in 10% formalin. The tissues were then embedded in
parafﬁn and serially sectioned (Sacura Sledge microtome) at
5–10 lm. Tissue sections were stained with Hematoxylin/
Eosin, Ziehl–Neelsen for acid-fast bacteria [38] and Berlin
blue for ferric iron [39].
Immunohistochemistry used a modiﬁcation of the avidin-
biotin-peroxidase complex (ABC) technique. Deparafﬁnized
sections were incubated with rabbit (primary) Ab against
M. tuberculosis (1:100 dilution, BP2027; Acris, Himmelreich,
Germany) for 4 h, and with a secondary biotinylated goat Ab
against rabbit-IgG (1:200 dilution, 21538; IHC Select, Milli-
pore, Billerica, MA, USA) at room temperature. Complexes
were disclosed with a chromogen of oxidized diaminobenzi-
dine-H2O2 reaction. Slides were viewed using a Nikon
Eclipse 800 microscope (Nikon Corporation, Tokyo, Japan)
and images were digitally captured using a CCD-SPOT RT
digital camera (Diagnostic Instruments Inc., Sterling Heights,
MI, USA) and then compiled using Adobe Photoshop CS3
software (Adobe Systems Inc., San Jose, CA, USA). Bacterial
clumps and acid-fast bacilli were observed at ·3000 total
magniﬁcation under oil.
In vivo MR imaging
MRI was performed on all mice before and, once every 5 min,
for a total of 30 min, after probe injection. Five mice were an-
aesthetized for imaging via subcutaneous injection of Ketamine
(80 mg/kg of body weight) and Xylazine (12 mg/kg). SPIO-
TBsAb probes (2 nmol/200 lL) were injected intravenously
through a tail vein. For MR imaging, T2-weighted fast spin-echo
imaging was used (TR = 3000; TE = 90; ﬁeld of view = 8).
The same radiologist did the quantitative analyses for all MR
images. Signal intensity (SI) was measured in deﬁned regions
of interest (ROI), which were in comparable locations within
a TB granulomatous lesion centre. In addition, the SI in the
ROI of the back muscle adjacent to the granulomatous area
was measured. The ROI size was chosen as 2/3 of the maxi-
mum diameter of the granulomatous area. Relative signal
enhancement was calculated using the SI measurements prior
to (SIpre) and after (SIpost) injection of the contrast agents
using the formula [(SIpost)SIpre)/SIpre] · 100, where SIpre
was the lesion signal intensity on the pre-enhanced scan (con-
trol) and SIpost was the lesion signal intensity on the post-
enhanced scan at 0–3 h.
Statistical analysis
Results are given as means + SDs. Statistical comparisons
used two-tailed Student’s t-tests. A p-value <0.05 was con-
sidered to be signiﬁcant.
Results
Synthesis and characterization of SPIO-TBsAb
The surface of an SPIO particle was modiﬁed to enable con-
jugation with TBsAb. Initially, dextran immobilized on the
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SPIO nanoparticles was cross-linked by epichlorohydrin. Sub-
sequently, the SPIO nanoparticles were treated with EDBE
to generate primary amine functional groups at the dextran
ends. Then, succinic anhydride (SA) was added to form
SPIO-EDBE-SA. Finally, TBsAb was conjugated with SPIO–
EDBE-SA in the presence of coupling agents to form SPIO-
TBsAb.
Figure 1 shows a TEM image of TBsAb-nanoparticles. This
TEM image indicates that the TBsAb-conjugated iron oxide
nanoparticles were well dispersed. The mean core size of
the TBsAb-nanoparticles was 3.8 ± 0.4 nm (calculated using
200 particles).
In aqueous solution, the relaxivity values, r1 and r2, of the
TBsAb-nanoparticles at 37.0 ± 0.1C and 20 MHz were
23 ± 3 and 151 ± 8 mM/s, respectively. These were slightly
lower than those of Resovist (r1 = 26 and r2 = 164 mM/s).
However, the (r1/r2) ratio of TBsAb-nanoparticles was similar
to that of Resovist.
In vitro characterization and imaging
To characterize the SPIO TBsAb probe, we ﬁrst examined
M. bovis BCG using Ziehl–Neelsen staining for acid-fast bac-
teria (Fig. 2a). The probes were then conjugated with bacte-
ria and identiﬁed by ferric iron staining with Berlin blue
(Fig. 2b).
The SPIO TBsAb probes that targeted Mtb were conﬁrmed
by T2-weighted MR imaging; reduced enhancement was shown
for probes incubated with bacteria. The reduction of signal
intensity (SI) in the presence of SPIO probes was concentra-
tion dependent (Fig. 2c). SPIO probes of 2, 1 and 0.5 mM con-
jugated with TB showed SIs, respectively, of 97.67 + 3.05,
131.67 + 4.51 and 257.33 + 5.03, which were comparable to
the probe alone (1 mM: SI = 90.75 + 2.47). Almost no signal
reduction (SI = 957.33 + 12.53) was found for the TB only
group compared with PBS (SI = 1073.43 + 13.62). This
indicated that the SPIO probes speciﬁcally targeted TB bacilli,
and the decline in SI on the enhanced MRI images for SPIO
probes was also consistent with iron oxide particles.
A similar decrease in SI on enhanced MR images was found
1 h after the bacteria-conjugated SPIO probes were incubated
with THP-1 monocytes. SI was signiﬁcantly reduced in the TB
group with the 1 mM probes (SI = 225.33 + 8.58) and 2 mM
probes (SI = 104 + 2.16) compared with the control group
without the probe (SI = 991 + 8.98) and the PBS only group
(SI = 1005.33 + 16.74). Similar reductions in MRI enhance-
ments in the TB groups with 1 and 2 mM probes were compa-
rable to the positive 1.0 mM probe only group
(SI = 112.33 + 3.68). Thus, the SPIO TBsAb probe was appli-
cable to TB probe-activated THP-1 monocyte trafﬁcking.
In vivo imaging
To check if TB infection could be detected by MR imaging in
vivo, SPIO TBsAb probes were intravenously administered to
FIG. 1. TEM image of MtbsAb-nanoparticles. The average core size
of MtbsAb-nanoparticles is 3.8 ± 0.4 nm. (Bar = 15 nm).
FIG. 2. In vitro and cell characterization of SPIO MtbsAb. (a) Ziehl–
Neelsen staining to identify acid-fast bacilli and (b) Berlin blue stain-
ing to identify the ferric iron of SPIO probes conjugated to bacteria.
Negative contrast enhancement of T2-weighted MR images is shown
for the SPIO MtbsAb probes incubated with bacteria. The signal
intensity (SI) is reduced by the presence of SPIO probes in a dose-
dependent manner: (1) 90.75 + 2.47 (1.0 mM Probe); (2)
97.67 + 3.05 (Mtb + 2.0 mM Probe); (3) 131.67 + 4.51
(Mtb + 1.0 mM Probe); (4) 257.33 + 5.03 (TB + 0.5 mM Probe); (5)
957.33 + 12.53 (Mtb + 0 mM Probe); (6) 1073.43 + 13.62 (PBS). (c)
No signal reduction is found in the PBS control group. (d) Similar
dose-dependent negative enhancement is also found 1 h after bacte-
ria-conjugated SPIO probes are incubated with THP-1 monocytes.
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TB-infected mice. At ½ h later, a clearly detectable MR signal
was observed in the TB granulomatous area, although the
highest target to background signal was observed at the 1-h
time point. As shown in Fig. 3, a signiﬁcant reduction of MR
signalling was found in TB granulomatous areas.
Signal enhancement evaluations used SI measurements
prior to (SIpre) and after (SIpost) injection of the contrast
agent. The T2-weighted reduction in signal enhancement was
c. 14-fold greater at the TB granulamatous sites compared
with the control sites 1 h after probe injection
()23.43 + 7.24% and )1.68 ± 1.32%; p <0.001).
Histology and immunohistochemistry
In C57BL/6 mice, the subcutis developed a granulomatous
lesion 1 month after infection. Some blood vessels could be
seen within these lesions along with aggregates of lymphocytes
and epithelioid macrophages. The development of these orga-
nized granulomas was progressive (Fig. 4a). To examine if the
TB lesions were correlated with the SPIO-MtbsAb MR signals,
immunohistochemistry was performed using anti-MtbsAb,
which indicated the interaction of TB Ag with TB Ab.
Immunohistochemical staining for MtbsAb expression was
noted in the granulomatous areas (Fig. 4b). Acid-fast bacilli
were scattered within the same lesion (Fig. 4c). Berlin blue
was then used to stain for ferric iron, which indicated the
probes’ conjugation to TB bacteria. Berlin blue staining SPIO
probes were located in the same area as MtbsAb (Fig. 4d).
Figure 4a–d shows co-localized pairs.
Discussion
The limited sensitivities of serological tests for detecting
mycobacterial antigens have encouraged the development of
more speciﬁc tests to diagnose the extrapulmonary form of
TB (ETB). An innovative probe comprised of super-paramag-
netic iron oxide (SPIO) nanoparticles conjugated with Mtb
surface antibody (MtbsAb-nanoparticles) was used to target
Mycobacterial antigens, which provided ultrasensitive imaging
of biomarkers involved with ETB infection. Previous investi-
gations to detect TB bacteria in relatively large sputum sam-
ple volumes used hybrid nanoparticles with a large iron core
and a thin ferrite shell (cannonballs (CB)) [41]. Our results
showed that MtbsAb-nanoparticles were signiﬁcantly conju-
gated with TB bacilli, in agreement with previous studies
[41]. Notably, the extent of contrast enhancement reduction
on magnetic resonance imaging for TB and monocytic THP1
cells was proportional to the concentration of MtbsAb-nano-
particles.
One major problem with ETB is its low activity in the
body, which makes its detection difﬁcult. When TBsAb-nano-
particles were administered to mice bearing TB granulomas
by intravenous injection, the granulomatous site was
detected on T2-weighted magnetic resonance images as a 14-
fold greater reduction in signal enhancement compared with
an opposing site with PBS injection, indicating a signiﬁcant
accumulation of contrast agent. This suggests the possibility
of obtaining speciﬁc targeting with a contrast agent, which
could result in lower required doses for clinical diagnosis.
Our results indicate that SPIO nanoparticles accumulate in
detectable amounts in TB granulomatous lesions. These ﬁnd-
ings further support the development of an SPIO probe using
an anti-human TB Ab. Because the magnetic iron oxide core
FIG. 3. In vivo SPIO TBsAb imaging in subcutaneous TB lesions of a
C57BL/6 mouse. A signiﬁcant 14-fold reduction in MR signal intensity
was found in the TB granulamatous areas compared with the control
areas 1 h after probe injection ()23.43 + 7.24 and )1.68 ± 1.32,
p <0.001). (a) Pre-injection and (b) post-injection.
FIG. 4. Correlations of HE, TB Ab, acid-fast and Berlin blue staining. The subcutaneous granulomatous lesions predominantly include lympho-
cytes and epithelioid macrophages. New blood vessel formation and large aggregates of lymphocytes and epithelioid macrophages are found in
these lesions. (a) The development of organized granulomas appears to be progressive. (b) Immunohistochemical staining for MtbsAb expression
is noted in the granulomatous area, whereas (c) acid-fast bacilli are scattered within the same lesions. (d) Berlin blue staining SPIO probes are
noted in the same area as MtbsAb. Berlin blue stains for ferric iron, which indicates the probes’ conjugation with TB bacteria.
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(c)
HE TBAb
(d)
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of SPIO-HD is widely used in MRI contrast agents to induce
T2 shortening, our results indicate the potential to image
similar cell behaviours in patients in a non-invasive manner.
This would allow the evaluation of existing treatment proto-
cols or modiﬁed protocols, which might ultimately provide
more favourable patient outcomes. Thus, MtbsAb-nanoparti-
cles may constitute a new non-invasive technology for the
diagnosis of extrapulmonary tuberculosis.
For this exploratory study, we used M. bovis BCG and rab-
bit anti-M tuberculosis as the antigen and antibody, respec-
tively. The cross-reactivity between rabbit and bovine sources
was not considered to be too high, although our results dem-
onstrated that SPIO conjugated with speciﬁc TB antibodies
showed signiﬁcant interactions with bovine BCG bacteria. A
dose-dependent reduction in signal enhancement was shown
for probes incubated with bacteria. This indicates that SPIO
probes speciﬁcally target TB, and the enhancement decline
seen on MRI for SPIO probes was also consistent with the
presence of iron oxide particles. However, additional studies
are warranted to investigate other, more speciﬁc antibodies
or antibody combinations to improve speciﬁcity.
The subcutis developed a TB granulamatous lesion
1 month after infection in this mouse model. Typical TB
granulomatous histology ﬁndings were identiﬁed, including
the presence of lymphocytes, epithelioid macrophages and
new blood vessel formation. Acid-fast bacilli were scattered
in the TB lesions, which corroborated the MtbsAb immuno-
histochemistry ﬁndings. This indicated an interaction
between Mtb Ag and Mtb Ab. The ferric iron stain Berlin
blue highlighted the same areas with MtbsAb, which indicated
the probes’ conjugation with TB bacteria.
Previous reports have shown that SPIO probes are not
cytotoxic and do not inﬂuence cell behaviour at particle
concentrations comparable to those we have used [32, 33,
42–44]. Our results showed minimal inﬂuence 1 h after the
bacteria-conjugated SPIO probe was incubated with THP-1
monocytes. SI was signiﬁcantly reduced in the groups with TB
and with 1 mM probes (SI = 225.33 + 8.58) and 2 mM probes
(SI = 104 + 2.16) compared with those groups without the
probe (SI = 991 + 8.98) and PBS only (SI = 1005.33 + 16.74).
Although the SPIO MtbsAb probe is a promising tool for Mtb
probe-activated THP-1 monocyte trafﬁcking, additional investi-
gations will be necessary using different bacterial loads in
order to evaluate probe sensitivity.
Our study had several limitations. We did not observe
the biodistribution of the SPIO MtbsAb probe in this study.
Another important limitation involved limited data for the
intravascular half-life of the SPIO Ab probe and its possible
liver deposition, which could affect the time that the parti-
cles are exposed to THP-1 monocytes located within a TB
lesion. This remains a subject for further investigation. In
addition, MRI cannot determine if SPIO nanoparticles are
speciﬁcally bound to bacteria/monocytes or if these particles
are endocytosed. This also remains a subject for future
research.
In conclusion, we have successfully prepared and charac-
terized biocompatible SPIO-MtbsAb nanoparticles. These
nanoparticles are hydrophilic, minimally cell cytotoxic at low
concentrations, and well dispersed under physiological condi-
tions. Moreover, MtbsAb-nanoparticles can target and detect
TB infection, as shown by both in vitro and in vivo MRI stud-
ies. Therefore, SPIO-MtbsAb nanoparticles may be used as
MRI contrast agents for detecting extrapulmonary TB.
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